临床研究
ENGLISH ABSTRACT
OPA1基因新发无义变异导致ADOA一家系临床表型和基因型分析
王莉红
王志立
陈晓
魏嘉
陈慷
崔龙江
作者及单位信息
·
DOI: 10.3760/cma.j.cn115989-20231227-00224
Clinical phenotype and genotype analysis of a family with autosomal dominant optic atrophy caused by a novel nonsense variant in OPA1
Wang Lihong
Wang Zhili
Chen Xiao
Wei Jia
Chen Kang
Cui Longjiang
Authors Info & Affiliations
Wang Lihong
Henan Provincial People's Hospital, Henan Eye Hospital, Zhengzhou 450003, China
Wang Zhili
Henan Provincial People's Hospital, Henan Eye Hospital, Zhengzhou 450003, China
Chen Xiao
Henan Provincial People's Hospital, Henan Eye Hospital, Zhengzhou 450003, China
Wei Jia
Henan Provincial People's Hospital, Henan Eye Hospital, Zhengzhou 450003, China
Chen Kang
Henan Provincial People's Hospital, Henan Eye Hospital, Zhengzhou 450003, China
Cui Longjiang
Henan Provincial People's Hospital, Henan Eye Hospital, Zhengzhou 450003, China
·
DOI: 10.3760/cma.j.cn115989-20231227-00224
0
0
0
0
0
0
PDF下载
APP内阅读
摘要

目的分析常染色体显性遗传性视神经萎缩(ADOA)一家系的临床表型及基因型。

方法采用家系调查研究方法,纳入2023年7—10月在河南省立眼科医院就诊的中国河南地区汉族ADOA一家系2代4名成员,包括2例患者。详细询问患者及其家系成员病史,并进行全面的眼科检查,包括视力、视野、眼底、视网膜电图(ERG)、视觉诱发电位(VEP)、光学相干断层扫描;同时进行听力、肌电图及颅脑磁共振检查以明确是否伴有全身异常。收集该家系4名成员的外周血,对先证者进行全外显子组测序,其他成员采用Sanger测序验证。对新发现的变异位点进行致病性和蛋白结构分析。

结果先证者女,15岁,左眼视力下降4年,双眼视神经萎缩,双眼黄斑区中心凹厚度稍变薄,神经节细胞复合体层厚度局部轻度变薄,VEP各波呈低振幅改变,部分视野缺失;全身检查未见明显听力障碍和肌张力异常。先证者母亲视神经部分区域萎缩,双眼黄斑区中心凹厚度稍变薄,VEP检查未见明显异常,ERG轻度异常。全外显子组测序结果显示,先证者及其母亲 OPA1基因外显子6出现杂合无义变异c.676C>T(p.Gln226Ter),该变异位点在HGMD数据库未见报道,千人基因组和gnomAD数据库未见收录,其可导致226位谷氨酰胺处发生提前终止。蛋白结构分析显示,OPA1蛋白p.Gln226Ter可造成蛋白与周围残基相结合的氢键改变,进而导致蛋白功能改变。根据ACMG指南,该变异可能致病。

结论该ADOA家系患者表现为青少年时期发病的双眼视神经萎缩,左眼为主; OPA1基因c.676C>T变异可能为该ADOA家系致病变异位点,该变异位点为首次报道。

常染色体显性遗传性视神经萎缩;家系;表型; OPA1基因 ;基因突变
ABSTRACT

ObjectiveTo analyze the clinical phenotype and the associated pathogenic genes in a family exhibiting autosomal dominant inherited optic atrophy (ADOA).

MethodsA pedigree analysis was conducted on a Han Chinese family with ADOA comprising two generations and four individuals from Henan Province.The family with two ADOA patients was recruited at Henan Eye Hospital between July and October 2023.Detailed medical histories were collected for the proband and family members.Comprehensive ophthalmologic evaluations were performed, including assessments of visual acuity, visual field, fundus photography, electroretinogram (ERG), visual evoked potential (VEP), and optical coherence tomography.Additionally, hearing, electromyography, and magnetic resonance imaging were performed on the proband to assess the presence of systemic symptoms.Peripheral blood samples were collected from four family members, and whole exome sequencing (WES) was performed on the proband, with subsequent validation via Sanger sequencing for the other family members.The pathogenicity and protein struture of the novel variant were analyzed.This study adhered to the Declaration of Helsinki.The study protocol was approved by the Ethics Committee of Henan Eye Hospital (No.HNEECKY-2019[15]).Written informed consent was obtained from each subject.

ResultsThe proband was a 15-year-old female with a 4-year history of vision loss in the left eye and optic atrophy, mild thinning of central macular foveal thickness, locally mild thinning of ganglion cell complex layer thickness, low VEP amplitude, and partial visual field defects in both eyes, and no significant hearing impairment or dystonia on systemic examination.The proband's mother had partial optic nerve atrophy and slightly decreased central macular foveal thickness in both eyes, and mild ERG abnormalities, but no significant VEP abnormalities.WES identified a heterozygous nonsense variant c. 676C>T (p.Gln226Ter) in exon 6 of the OPA1 gene of the proband and her mother.This variant has not been previously reported in the literature, nor is it listed in the Human Gene Mutation Database, the Thousand Genomes Project, or the Genome Aggregation Database, which results in a premature termination codon at glutamine position 226.Protein structure analysis showed that p. Gln226Ter of the OPA1 protein induces alterations in the hydrogen bonding of the protein binding to surrounding residues, which in turn leads to protein function alterations.The variant was classified as potentially pathogenic according to the ACMG standards and guidelines.

ConclusionsPatients in this ADOA family present with adolescent-onset optic atrophy in both eyes, with a predominance in the left eye.The c. 676C>T variant in OPA1 gene might be the causative variant in this ADOA family.Notably, this is the first report of this specific variant.

Optic atrophy, autosomal dominant;Pedigree;Phenotype; OPA1 gene ;Gene mutation
Cui Longjiang, Email: mocdef.qabq391506519
引用本文

王莉红,王志立,陈晓,等. OPA1基因新发无义变异导致ADOA一家系临床表型和基因型分析 [J]. 中华实验眼科杂志,2024,42(10):932-937.

DOI:10.3760/cma.j.cn115989-20231227-00224

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
常染色体显性遗传性视神经萎缩(autosomal dominant optic atrophy,ADOA)的发病率为1/50 000~1/10 000,主要表现为不同程度的视力下降,多在儿童期隐匿发病 [ 1 ]OPA1(3q29,OMIM 605290)基因变异占ADOA患者的70%~90%,该基因由29个外显子组成(NM_015560.3),共8种转录本;其编码一种影响线粒体形态和功能的GTPase相关蛋白,具有线粒体前导序列、GTPase结构域、中央动力结构域及2个末端螺旋卷曲结构域 [ 2 ]。截至目前,人类基因突变数据库(Human Gene Mutation Database,HGMD)记录 OPA1基因693种变异,Leiden开放变异数据库(https://www.lovd.nl/OPA1)现报道705种 OPA1基因变异,变异主要集中在GTPase结构域及C端螺旋卷曲结构域。ADOA是一种罕见的进行性和不可逆性致盲疾病,是常见的遗传性视神经病变之一。尽管对其发病机制的理解越来越深入,但目前仍缺少治疗ADOA的有效方法 [ 3 , 4 ]。且当患者的其他家庭成员无视力损害表现时,临床医生在工作中很难对患者的视力丧失做出遗传性视神经疾病的诊断,探索基因改变对于了解可能发生的全身改变以及眼科疾病预后有很大帮助。本研究采用全外显子组测序方法对ADOA一家系进行基因检测,并分析患者的临床表型,为ADOA的临床诊断提供参考。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
中国眼遗传病诊疗小组中国眼科遗传联盟眼遗传病基因诊断方法专家共识[J]. 中华实验眼科杂志 201836(7)∶481488. DOI: 10.3760/cma.j.issn.2095-0160.2018.07.001 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Arruti N Rodríguez-Solana P Nieves-Moreno M et al. OPA1 dominant optic atrophy:diagnostic approach in the pediatric population [J]. Curr Issues Mol Biol 202345(1)∶465478. DOI: 10.3390/cimb45010030 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Ferro Desideri L Traverso CE Iester M Current treatment options for treating OPA1 -mutant dominant optic atrophy [J]. Drugs Today (Barc) 202258(11)∶547552. DOI: 10.1358/dot.2022.58.11.3448291 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Skidd PM Lessell S Cestari DM . Autosomal dominant hereditary optic neuropathy (ADOA):a review of the genetics and clinical manifestations of ADOA and ADOA+[J]. Semin Ophthalmol 201328(5-6)∶422426. DOI: 10.3109/08820538.2013.825296 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Riggs ER Andersen EF Cherry AM et al. Technical standards for the interpretation and reporting of constitutional copy-number variants:a joint consensus recommendation of the American Colleg e of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen) [J]. Genet Med 202022(2)∶245257. DOI: 10.1038/s41436-019-0686-8 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Del Dotto V Fogazza M Lenaers G et al. OPA1:how much do we know to approach therapy?[J]. Pharmacol Res 2018131199210. DOI: 10.1016/j.phrs.2018.02.018 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Kurosaki T Maquat LE . Nonsense-mediated mRNA decay in humans at a glance[J]. J Cell Sci 2016129(3)∶461467. DOI: 10.1242/jcs.181008 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Weisschuh N Schimpf-Linzenbold S Mazzola P et al. Mutation spectrum of the OPA1 gene in a large cohort of patients with suspected dominant optic atrophy:identification and classification of 48 novel variants [J/OL]. PLoS One 202116(7)∶e0253987[2024-25-25]. https://pubmed.ncbi.nlm.nih.gov/34242285/. DOI: 10.1371/journal.pone.0253987 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Kushnareva YE Gerencser AA Bossy B et al. Loss of OPA1 disturbs cellular calcium homeostasis and sensitizes for excitotoxicity[J]. Cell Death Differ 201320(2)∶353365. DOI: 10.1038/cdd.2012.128 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Wong D Harvey JP Jurkute N et al. OPA1 dominant optic atrophy:pathogenesis and therapeutic targets [J]. J Neuroophthalmol 202343(4)∶464474. DOI: 10.1097/WNO.0000000000001830 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Zeviani M Carelli V Mitochondrial retinopathies[J/OL]. Int J Mol Sci 202123(1)∶210[2024-05-25]. https://pubmed.ncbi.nlm.nih.gov/35008635/. DOI: 10.3390/ijms23010210 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Ahmad KE Davis RL Sue CM . A novel OPA1 mutation causing variable age of onset autosomal dominant optic atrophy plus in an Australian family [J]. J Neurol 2015262(10)∶23232328. DOI: 10.1007/s00415-015-7849-6 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Kane MS Alban J Desquiret-Dumas V et al. Autophagy controls the pathogenicity of OPA1 mutations in dominant optic atrophy [J]. J Cell Mol Med 201721(10)∶22842297. DOI: 10.1111/jcmm.13149 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Baker N Wade S Triolo M et al. The mitochondrial protein OPA1 regulates the quiescent state of adult muscle stem cells [J]. Cell Stem Cell 202229(9)∶13151332. DOI: 10.1016/j.stem.2022.07.010 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Carelli V La Morgia C Yu-Wai-Man P Mitochondrial optic neuropathies[J]. Handb Clin Neurol 20231942342. DOI: 10.1016/B978-0-12-821751-1.00010-5 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Toomes C Marchbank NJ Mackey DA et al. Spectrum,frequency and penetrance of OPA1 mutations in dominant optic atrophy [J]. Hum Mol Genet 200110(13)∶13691378. DOI: 10.1093/hmg/10.13.1369 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Thiselton DL Alexander C Taanman JW et al. A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy [J]. Invest Ophthalmol Vis Sci 200243(6)∶17151724.
返回引文位置Google Scholar
百度学术
万方数据
[18]
Sarzi E Seveno M Piro-Mégy C et al. OPA1 gene therapy prevents retinal ganglion cell loss in a dominant optic atrophy mouse model [J/OL]. Sci Rep 20188(1)∶2468[2024-05-25]. https://pubmed.ncbi.nlm.nih.gov/29410463/. DOI: 10.1038/s41598-018-20838-8 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
崔龙江,Email: mocdef.qabq391506519
B

王莉红:酝酿和设计试验、实施研究、采集数据、分析/解释数据、起草及修改文章;王志立、陈晓:实施研究、采集数据、分析/解释数据;魏嘉、陈慷:酝酿和设计试验、实施研究、采集数据、分析/解释数据;崔龙江:酝酿和设计试验、实施研究、采集数据、分析/解释数据、对文章的知识性内容作批评性审阅及定稿

C
所有作者均声明不存在利益冲突
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号